Immunic (IMUX) News Today $0.84 -0.01 (-1.31%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period What is Leerink Partnrs' Estimate for Immunic Q1 Earnings?August 12 at 4:08 AM | marketbeat.comWilliam Blair Predicts Immunic's Q1 Earnings (NASDAQ:IMUX)August 12 at 4:08 AM | marketbeat.comWilliam Blair Forecasts Immunic's Q1 Earnings (NASDAQ:IMUX)August 12 at 3:47 AM | americanbankingnews.comImmunic (NASDAQ:IMUX) Announces Quarterly Earnings ResultsAugust 11 at 11:33 AM | marketbeat.comImmunic, Inc. (IMUX) latest stock news and headlines – Yahoo FinanceAugust 10 at 6:17 PM | sg.finance.yahoo.comD. Boral Capital Reiterates Buy Rating for Immunic (NASDAQ:IMUX)August 9, 2025 | marketbeat.comImmunic reports promising Phase 2 data for lead drug candidate in progressive MS - ICYMIAugust 9, 2025 | proactiveinvestors.comImmunic (IMUX) Q2 Loss Widens 25%August 8, 2025 | theglobeandmail.comImmunic advances MS drug program with Phase 3 trials fully enrolledAugust 7, 2025 | proactiveinvestors.comImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | gurufocus.comImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update | ...August 7, 2025 | gurufocus.comImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | prnewswire.comImmunic (IMUX) to Release Quarterly Earnings on ThursdayAugust 7, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Receives $7.50 Average Target Price from BrokeragesAugust 5, 2025 | americanbankingnews.comImmunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 31, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Stock Price Down 3.6% - Time to Sell?July 29, 2025 | marketbeat.comImmunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS TrialJuly 25, 2025 | msn.comImmunic board authorizes up to 35 million stock ... - Investing.comJuly 13, 2025 | investing.comImmunic, Inc. (IMUX) Latest Stock News & Headlines - Yahoo FinanceJuly 9, 2025 | ca.finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by BrokeragesJuly 6, 2025 | marketbeat.comImmunic CEO discusses Phase 2 multiple sclerosis study success - ICYMIJune 28, 2025 | proactiveinvestors.comImmunic reveals long-term data supporting potential of MS drug vidofludimus calciumJune 24, 2025 | proactiveinvestors.comImmunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple SclerosisJune 24, 2025 | prnewswire.comImmunic showcases MS drug data at BIO International Convention in Boston - ICYMIJune 21, 2025 | proactiveinvestors.comImmunic, Inc. (NASDAQ:IMUX) Chairman Duane Nash Purchases 20,000 SharesJune 17, 2025 | insidertrades.comInsider Buying: Immunic, Inc. (NASDAQ:IMUX) Chairman Purchases 20,000 Shares of StockJune 16, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Short Interest UpdateJune 15, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by BrokeragesJune 11, 2025 | marketbeat.comImmunic Post-Readout: Reiterating Strong Buy As Big Drop Appears UnwarrantedJune 9, 2025 | seekingalpha.comMillennium Management LLC Has $580,000 Stake in Immunic, Inc. (NASDAQ:IMUX)June 9, 2025 | marketbeat.comImmunic completes Phase 3 multiple sclerosis trial enrollment - ICYMIJune 7, 2025 | proactiveinvestors.comInsider Buying: Immunic, Inc. (NASDAQ:IMUX) CEO Purchases 15,000 Shares of StockJune 6, 2025 | marketbeat.comImmunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trialsJune 5, 2025 | proactiveinvestors.comImmunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MSJune 5, 2025 | prnewswire.comQ2 Earnings Forecast for Immunic Issued By Leerink PartnrsJune 5, 2025 | marketbeat.comImmunic raises $65M in public offering to fund clinical trialsJune 3, 2025 | proactiveinvestors.comImmunic raises $65M in public offering to fund clinical trialsJune 3, 2025 | proactiveinvestors.comImmunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public OfferingJune 3, 2025 | prnewswire.comImmunic to Participate in Investor, Scientific and Industry Conferences in JuneJune 2, 2025 | prnewswire.comD. Boral Capital Cuts Immunic (NASDAQ:IMUX) Price Target to $10.00May 30, 2025 | marketbeat.comImmunic announces public offering of warrants to fund trialsMay 30, 2025 | investing.comImmunic shares fall 12% after pricing of $65 million underwritten public offering to fund trialsMay 29, 2025 | msn.comImmunic unveils pricing of $65M underwritten public offeringMay 29, 2025 | proactiveinvestors.comImmunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public OfferingMay 29, 2025 | prnewswire.comImmunic, Inc. Announces Proposed Public OfferingMay 28, 2025 | prnewswire.comImmunic (NASDAQ:IMUX) Receives Buy Rating from B. RileyMay 25, 2025 | marketbeat.comImmunic Analyst Ratings and Price Targets | NASDAQ:IMUX | BenzingaMay 24, 2025 | benzinga.comJanus Henderson Group PLC Cuts Stock Holdings in Immunic, Inc. (NASDAQ:IMUX)May 23, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by AnalystsMay 19, 2025 | marketbeat.comImmunic (IMUX) Expected to Announce Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.com Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address IMUX Media Mentions By Week IMUX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUX News Sentiment▼0.610.73▲Average Medical News Sentiment IMUX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUX Articles This Week▼224▲IMUX Articles Average Week Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Inventiva News Canopy Growth News Tonix Pharmaceuticals News Corvus Pharmaceuticals News Abeona Therapeutics News Benitec Biopharma News Candel Therapeutics News Aldeyra Therapeutics News Inhibrx Biosciences News Arcturus Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMUX) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access